Furthermore, the PI3K/Akt pathway activation in tumors may be accompanied by the tumor suppressor PTEN inactivating mutations, thus boosting survival advantages and the uncontrolled proliferation of cancer cells, lacking the PTEN-mediated cell cycle arrest in the G1 phase [70]. The gene discussed is AKT1; the disease is cancer.